Not fair but reasonable is the conclusion of the Independant experts report. Not fair because the valuation per issued share after the proposed subscription is considered less than valuation per issued share before proposed subscription, and reasonable because the advantages out number the disadvantages.
interesting to see that additional funds coming their way through the subscription are all directed to PBT4 and none to PBT2, although they do state that they are looking at alternative indications for PBT2 which I am sure refers to the bacterial anti resistance studies performed by Uni of QLD.
excerpt from announcement.
The Company continues progressing its product candidate for Parkinsonian movement disorders, PBT‐434, commencing its first in‐human study in healthy volunteers. The Company intends expanding research and development and pre‐clinical activities and commencing clinical trials for product candidates, including PBT‐434, prospectively PBT2 for alternative indications and development of other compounds.
- Forums
- ASX - By Stock
- ATH
- Ann: Notice of General Meeting/Proxy Form
Ann: Notice of General Meeting/Proxy Form, page-2
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $200 | 66.66K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
54 | 75258609 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 4967441 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
54 | 75258609 | 0.002 |
23 | 117810099 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 4967441 | 3 |
0.004 | 132321201 | 25 |
0.005 | 25242406 | 26 |
0.006 | 23031950 | 19 |
0.007 | 47726651 | 22 |
Last trade - 10.00am 10/09/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |